As the multidrug-and extensively drug-resistant tuberculosis (M/XDR-TB) is spreading at alarming rates in the World Health Organization (WHO) European Region -about 81,000 (18.4%) of the estimated 440,000 patients worldwide with MDR-TB are considered to live in this region -the WHO Regional Office for Europe has launched an action plan to contain the spread of drugresistant TB in the region by the end of 2015 [1, 2] . This action plan was endorsed on 15 September 2011 by all 53 countries of the WHO European Region [3] .
The plan has been prepared in consultation with representatives of the 53 countries of the WHO European Region, experts, patients and communities affected by the disease. The plan takes into account new diagnostic techniques, patient-centred models of care and services tailored to special populations. It includes six strategic directions, such as collaboration on more effective drugs, vaccines and testing, and seven areas of intervention, such as improving access to testing and treatment. • to decrease by 20% the proportion of MDR-TB cases among previously treated patients, • to diagnose at least 85% of estimated MDR-TB cases, • to treat successfully at least 75% of patients notified as having MDR-TB.
If fully implemented, the plan is expected, by 2015, to diagnose 225,000 MDR-TB patients within three days of presenting to a healthcare service with TB symptoms, to successfully treat 127,000 MDR-TB patients, and to prevent the emergence of 250,000 new MDR-TB and 13,000 new XDR-TB cases. According to WHO Regional Office for Europe, this would interrupt the transmission of MDR-TB and save 120,000 lives.
